Coronary Heart Disease
Conditions
Keywords
CV Risk, Cardiovascular Disease, Atherosclerosis, Acute coronary syndrome
Brief summary
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in subjects with clinical manifestations of cardiovascular disease (chronic coronary heart disease (CHD) and post Acute Coronary Syndrome (ACS)). With respect to efficacy, the key purpose of this integrated analysis is to evaluate the effects of darapladib on the following endpoints: urgent coronary revascularization for myoacrdial ischemia, fatal/non-fatal stroke, time to subsequent Major Adverse Cardiovascular Event (MACE), and heart failure requiring hospitalization. The first occurrent of MACE, Major and total coronary events as well as the individual components of MACE will also be evaluated descriptively.
Detailed description
The objective of the integrated safety analysis is to characterize the safety profile of darapladib in subjects with clinical manifestations of cardiovascular disease (chronic coronary heart disease (CHD) and post Acute Coronary Syndrome (ACS)). The purpose of the integrated efficacy analysis is to test the effects of darapladib on select endpoints which are not part of the testing hierarchies associated with the individual studies, namely: urgent coronary revascularization for myocardial ischemia, stroke, subsequent MACE, and heart failure requiring hospitalization, For all other endpoints, the intent of the integrated analysis is to provide increased precision of the estimated effects of darapladib.
Interventions
DRUGdarapladib
darapladib enteric coated tablets 160 mg
DRUGplacebo
placebo
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* This is an integrated analysis therefore inclusion criteria are not applicable.
Exclusion criteria
* This is an integrated analysis therefore
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time to first occurrence of urgent coronary revascularization for myocardial ischemia | visits occur at month 1,3,6, and every 6 months thereafter until 1500 first occurrence MACE events have occurred in each study. It is anticipated that the median follow-up time will be approximately 3 years in each study. | time to the first occurrence of any urgent coronary revascularization for myocardial ischemia |
| The time to first occurrence of stroke (fatal/non-fatal) | visits occur at month 1,3,6, and every 6 months thereafter until 1500 first occurrence MACE events have occurred in each study. It is anticipated that the median follow-up time will be approximately 3 years in each study. | time to the first occurrence of stroke (fatal or non-fatal) |
| The time to subsequent Major Adverse Cardiovascular Events (MACE) | visits occur at month 1,3,6, and every 6 months thereafter until 1500 first occurrence MACE events have occurred in each study. It is anticipated that the median follow-up time will be approximately 3 years in each study. | time to subsequent composite of MACE (CV death, non-fatal MI or non-fatal stroke) |
| The time to first occurrence of heart failure requiring hospitalization | visits occur at month 1,3,6, and every 6 months thereafter until 1500 first occurrence MACE events have occurred in each study. It is anticipated that the median follow-up time will be approximately 3 years in each study. | time to the first occurrence of heart failure requiring hospitalization |
Outcome results
None listed